LTRN · Lantern Pharma Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $1.72M | - | $2.44M | $3.07M | $3.26M | - | $3.72M | $3.89M | $4.25M | - |
| SG&A | $1.68M | - | $1.91M | $1.58M | $1.51M | - | $1.46M | $1.52M | $1.48M | - |
| Total Operating Expenses | $3.41M | - | $4.35M | $4.65M | $4.77M | - | $5.18M | $5.41M | $5.73M | - |
| D&A | $3.9K | - | - | - | $4.1K | - | - | - | $4.1K | - |
| Operating Income | ($3.41M) | - | ($4.35M) | ($4.65M) | ($4.77M) | - | ($5.18M) | ($5.41M) | ($5.73M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($3.33M) | - | ($4.18M) | ($4.33M) | ($4.54M) | - | ($4.51M) | ($4.96M) | ($5.44M) | - |
| EPS - Basic | ($0.30) | - | ($0.39) | ($0.40) | ($0.42) | - | ($0.42) | ($0.46) | ($0.51) | - |
| EPS - Diluted | ($0.30) | - | ($0.39) | ($0.40) | ($0.42) | - | ($0.42) | ($0.46) | ($0.51) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.92M | $4.42M | $8.39M | $6.06M | $6.38M | $7.51M | $8.10M | $12.98M | $18.36M | $21.94M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Current Assets | $7.06M | $10.80M | $13.46M | $17.20M | $20.82M | $25.25M | $29.92M | $35.29M | $39.47M | $43.34M |
| Total Assets | $7.22M | $11.04M | $13.63M | $17.42M | $21.10M | $25.57M | $30.29M | $35.59M | $39.73M | $43.65M |
| Current Liabilities | $3.78M | $4.50M | $4.04M | $4.88M | $4.29M | $4.33M | $3.60M | $4.60M | $3.95M | $2.68M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $3.78M | $4.50M | $4.04M | $4.90M | $4.32M | $4.38M | $3.70M | $4.66M | $3.97M | $2.74M |
| Stockholders' Equity | $3.45M | $6.53M | $9.59M | $12.52M | $16.78M | $21.19M | $26.60M | $30.93M | $35.77M | $40.91M |
| Retained Earnings | ($96.47M) | ($93.15M) | ($89.07M) | ($84.89M) | ($80.56M) | ($76.03M) | ($70.15M) | ($65.64M) | ($60.69M) | ($55.24M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($3.77M) | - | - | - | ($4.38M) | - | - | - | ($3.07M) | - |
| Investing Cash Flow | $4.25M | - | - | - | $3.24M | - | - | - | ($556.2K) | - |
| Financing Cash Flow | - | - | - | - | - | - | - | - | $54.7K | - |
| CapEx | - | - | - | - | $1.2K | - | - | - | $2.2K | - |
| Free Cash Flow | - | - | - | - | ($4.38M) | - | - | - | ($3.07M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | 0.96 | - | - | - | 0.56 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -46.1% | - | -30.7% | -24.9% | -21.5% | - | -14.9% | -13.9% | -13.7% | - |
| Return on equity | -96.6% | - | -43.6% | -34.6% | -27.0% | - | -16.9% | -16.0% | -15.2% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.87 | 2.40 | 3.33 | 3.52 | 4.86 | 5.83 | 8.31 | 7.67 | 9.98 | 16.18 |
| Quick ratio | 1.87 | 2.40 | 3.33 | 3.52 | 4.86 | 5.83 | 8.31 | 7.67 | 9.98 | 16.18 |
| Cash ratio | 1.30 | 0.98 | 2.08 | 1.24 | 1.49 | 1.73 | 2.25 | 2.82 | 4.64 | 8.19 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 2.10 | 1.69 | 1.42 | 1.39 | 1.26 | 1.21 | 1.14 | 1.15 | 1.11 | 1.07 |
| Liabilities / Assets | 0.52 | 0.41 | 0.30 | 0.28 | 0.20 | 0.17 | 0.12 | 0.13 | 0.10 | 0.06 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 4.5x | - | 4.9x | 2.7x | 2.3x | - | 1.5x | 1.6x | 2.6x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 28.7% | - | 16.0% | 14.0% | 16.7% | - | -47.0% | -4.2% | -33.7% | - |
| Net income growth (YoY) | 26.6% | - | 7.3% | 12.7% | 16.6% | - | -42.5% | -4.5% | -40.7% | - |
| EPS growth (YoY) | 28.6% | - | 7.1% | 13.0% | 17.6% | - | -44.8% | -12.2% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | -42.5% | - | - | - | 18.5% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -79.5% | -69.2% | -64.0% | -59.5% | -53.1% | -48.2% | -41.4% | -35.9% | -32.0% | -27.0% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Lantern Pharma Inc. against the 5 most active filers in the same SIC group.